Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- Japan, South Korea Sign MOU for Regulatory Affairs
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- PMDA, AMED Ink Pact to Spur Commercialization of Novel Drugs
August 20, 2015
- PAFSC’s 2nd Committee to Discuss AbbVie’s Combination Drug for Hepatitis C on Aug. 31
August 19, 2015
- PAFSC 2nd Committee to Discuss Orphan Drug Designation for 3 APIs on Aug. 31
August 19, 2015
- 18 Firms Win Approval for Jzoloft Generics, 25 for Exforge Generics
August 18, 2015
- Govt, Pharma Leaders to Meet on Aug. 24 over “Comprehensive Strategy”
August 18, 2015
- FY2016 Drug Pricing Reform
August 18, 2015
- PAFSC First Committee to Review Glatiramer, Add’l Indication for Xarelto on Aug. 28
August 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 21 - August 9
August 10, 2015
- MHLW Notifies of Package Insert Changes for Daklinza, Sunvepra
August 10, 2015
- “Greater Emphasis” Will Need to Be Placed on R&D in Field of Oncology: AMED President
August 7, 2015
- MHLW Calls for Package Insert Revision for Inavir, Relenza
August 7, 2015
- Health Minister Reviewing Ways to Strengthen Guidance to Optimize Ethical Drug Ads: Senior Vice Minister Nagaoka
August 6, 2015
- PAFSC 2nd Committee Endorses Approval of AZ’s Vandetanib
August 5, 2015
- Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification
August 4, 2015
- PAFSC’s First Committee Supports Approval of Actelion’s Tracleer for Digital Ulcers in Generalized Scleroderma
August 3, 2015
- AMED Sets Up 5-Step Process to Pick Licensees of Academic Drug Seeds
July 30, 2015
- MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
July 29, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…